David Kirske - CTi Biopharma CFO, Executive Vice President
President
Mr. David H. Kirske is Chief Financial Officer of the company. He joined the company earlier in 2017 and served as the Principal Financial and Accounting Officer prior to being appointed Chief Financial Officer. Mr. Kirske financial management experience includes overseeing finance, accounting, operations, and capitalization, in both debt and equity. Prior to joining CTI BioPharma, he was an independent CFO consultant sinceJanuary 2013. Prior to his time as a consultant, he served as Vice President and CFO of Helix BioMedix where he managed all financial and administrative activities. Previously, he was the Treasurer and Corporationrationrate Controller for F5 Networks and Redhook Brewery where he managed both corporate and international entities, as well as being part of the management teams that led and executed each company successful initial public offerings. Earlier in his career, he held a controllership position at Cray Computer since 2017.
| Age | 69 |
| Tenure | 8 years |
| Phone | 206 282 7100 |
| Web | https://www.ctibiopharma.com |
CTi Biopharma Management Efficiency
The company has return on total asset (ROA) of (0.2858) % which means that it has lost $0.2858 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.1875) %, meaning that it created substantial loss on money invested by shareholders. CTi Biopharma's management efficiency ratios could be used to measure how well CTi Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.CTi Biopharma Corp currently holds 49.96 M in liabilities. CTi Biopharma Corp has a current ratio of 3.19, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about CTi Biopharma's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 9 records | PRESIDENT Age | ||
| Les Tari | Cidara Therapeutics | N/A | |
| Laura Navalta | Cidara Therapeutics | ||
| Esteban Masuda | Rigel Pharmaceuticals | 63 | |
| Erik Verner | Corvus Pharmaceuticals | 59 | |
| Gregory Zante | Viking Therapeutics | 53 | |
| Yaron Naos | Protalix Biotherapeutics | 61 | |
| Jeffrey Stein | Cidara Therapeutics | 70 | |
| Joseph Lasaga | Rigel Pharmaceuticals | 50 | |
| William Jones | Corvus Pharmaceuticals | 59 | |
Management Performance
| Return On Equity | -10.19 | |||
| Return On Asset | -0.29 |
CTi Biopharma Corp Leadership Team
Elected by the shareholders, the CTi Biopharma's board of directors comprises two types of representatives: CTi Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CTi. The board's role is to monitor CTi Biopharma's management team and ensure that shareholders' interests are well served. CTi Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CTi Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jennifer Smith, VP Biometrics | ||
| Ed Bell, Director - Investor Relations | ||
| James Fong, Ex Officer | ||
| Bruce Bennett, VP Operations | ||
| John Volpone, Ex Staff | ||
| David Kirske, CFO, Executive Vice President | ||
| MBA MD, CEO and President |
CTi Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CTi Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -10.19 | |||
| Return On Asset | -0.29 | |||
| Profit Margin | (0.91) % | |||
| Operating Margin | (0.74) % | |||
| Current Valuation | 1.26 B | |||
| Shares Outstanding | 131.88 M | |||
| Shares Owned By Insiders | 5.49 % | |||
| Shares Owned By Institutions | 83.28 % | |||
| Number Of Shares Shorted | 11.27 M | |||
| Price To Earning | (1.68) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Other Consideration for investing in CTi Stock
If you are still planning to invest in CTi Biopharma Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the CTi Biopharma's history and understand the potential risks before investing.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |